High Intensity Aerobic Exercise Training and Immune Cell Mobilization in Patients With Lung Cancer (HI AIM)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- Herlev Hospital
- Enrollment
- 54
- Locations
- 1
- Primary Endpoint
- Circulating NK cells
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to investigate if high-intensive training can mobilize and activate the immune system, and thereby enhance the effect of the conventional treatment of lung cancer patients. An important aspect of this study will investigate if the presence of various proteins and cells in blood and tumor biopsies can verify or predict the effect of the high-intensive training. In this clinical trial, patients with lung cancer will combine their conventional therapy with a six-week exercise program.
Detailed Description
Research has shown that exercise training has several beneficial effects in cancer patients and survivors both during and after anti-cancer treatment, including improved physical function, reduction of symptoms, reduction of side effects and improved quality of life (QoL). In addition, a physical active lifestyle is associated with reduced risk of some cancers. Recent data in mouse models have shown that tumor-bearing mice randomized to a voluntary wheel running group showed over 60% reduction in tumor incidence and progression in several tumor models. Moreover, the mouse data clearly showed homing of T and natural killer (NK) cells to tumors in an exercise dependent manner, underscoring that exercise may render patients more prone to respond to therapy. However, most of the underlying biological mechanisms leading to the documented beneficial effects of physical exercise in relation to cancer are yet unknown, but exercise-mediated changes in hormone levels, inflammation and immune cell function are thought to play a key role. Included participants will be randomized 1:1 to an intervention group and a control group. Participants in the intervention group will receive a six-weeks exercise-based intervention with supervised and group-based exercise training three times a week at the hospital setting. Each training session will consist of intermediate and high intensity interval training. The exercise-based intervention will be combined with standard oncological treatments; checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Participants in the control group will still receive standard oncological treatments; immune checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance.
Investigators
Per thor Straten
Professor
Herlev Hospital
Eligibility Criteria
Inclusion Criteria
- •Metastatic non-small cell lung cancer
- •Measurable disease according to RECIST 1.1
- •Age ≥ 18 years
- •Treatment with immune checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance
- •Eastern Cooperative Oncology Group (ECOG) performance status score (PS) ≤2
- •Preferably metastasis suitable for biopsy
- •Normal marrow function as defined below:
- •White blood cell count (WBC) ≥ 2 x 10⁹/L
- •Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L
- •Hemoglobin ≥ 6.0 mmol/l
Exclusion Criteria
- •Any physical condition that hinder the execution of physical exercise, as assessed by the referring oncologist and by a physiotherapist
- •Severe dyspnea that hinder the execution of high intensity aerobic exercise training, as assessed by the referring oncologist
- •Symptomatic brain metastases
- •Dementia, psychotic disorders, or other cognitive diseases or conditions that hinder participation in a clinical exercise-based trial, as assessed by the referring oncologist
- •Unstable medical disease or history of serious or concurrent illness; any medical condition that might be aggravated by exercise training or that cannot be controlled, including, but not restricted to congestive heart failure (NYHA class III-IV), unstable angina pectoris, implantable cardioverter defibrillator (ICD), or myocardial infarction within 6 months
- •A condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications. Inhaled or topical steroids and adrenal replacement doses ≤ 10 mg daily prednisone equivalents are permitted
- •Use of beta blockers
- •Any systemic infections within the last 4 weeks
- •Patients who receives chemotherapy as monotherapy
- •In patients with documented bone metastases; patients with:
Outcomes
Primary Outcomes
Circulating NK cells
Time Frame: 0 - 36 months
Flow cytometry will be used to analyse and determine amount of circulating NK cells. The analysis will focus on absolute counts of NK cells, but also surface expression of various surface markers of interest.
Secondary Outcomes
- Maximal aerobic capacity(0 - 36 months)
- Circulating T cells and B cells.(0 - 36 months)
- Circulating serum markers of inflammation(0 - 36 months)
- Overall survival(0 - 36 months)
- Progression free survival (PFS)(0 - 36 months)